Clinical trials
Phase 2 Biliary Tract Neoplasms trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
76 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2010 | 2 |
| 2012 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 5 |
| 2018 | 5 |
| 2019 | 3 |
| 2020 | 5 |
| 2021 | 6 |
| 2022 | 5 |
| 2023 | 2 |
| 2024 | 8 |
| 2025 | 14 |
| 2026 | 17 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 27 |
| Completed | 17 |
| Unknown status | 17 |
| Not yet recruiting | 9 |
| Active, not recruiting | 5 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Peking Union Medical College Hospital | 11 |
| Shanghai Zhongshan Hospital | 6 |
| Fudan University | 4 |
| Sun Yat-sen University | 4 |
| Tianjin Medical University Cancer Institute and Hospital | 4 |
| AstraZeneca | 3 |
| Haitao Zhao, MD | 3 |
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 3 |
| Bayer | 2 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Biliary Tract Neoplasms | 76 |
| Cholangiocarcinoma | 8 |
| Gallbladder Neoplasms | 7 |
| Colorectal Neoplasms | 4 |
| Stomach Neoplasms | 4 |
| Bile Duct Neoplasms | 3 |
| Pancreatic Neoplasms | 3 |
| Breast Neoplasms | 2 |
| Endometrial Neoplasms | 2 |
| Ovarian Neoplasms | 2 |
Trials
Showing 1 to 25 of 76. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.